|
|
|
|
|
| Ferreira,Vinicius Lins; Borba,Helena Hiemisch Lobo; Wiens,Astrid; Pedroso,Maria Lucia Alves; Radunz,Vanessa Ferreira de Camargo; Ivantes,Cláudia Alexandra Pontes; Kuniyoshi,Aline Satie Oba; Pontarolo,Roberto. |
| ABSTRACT Background This study aimed to evaluate the clinical effectiveness in terms of sustained virological response and tolerability of available second generation direct-acting antivirals in Brazilian patients. Methods This was a retrospective observational study conducted in six centers in Southern Brazil. The sample comprised adult patients who were chronically infected with hepatitis C virus, regardless of virus genotype, fibrosis stage, or prior treatment. Statistical analysis was performed to compare the effectiveness among the treatments, and also to uncover the factors influencing the achievement of sustained virological response. Results A total of 296 patients were included in the study, with the majority receiving sofosbuvir with... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Brazil; Direct-acting antivirals; Hepatitis C; Observational study. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000300186 |
| |
|
|
| Wiens,Astrid; Borba,Helena Hiemisch Lobo; Leonart,Letícia Paula; Tonin,Fernanda Stumpf; Steimbach,Laiza Maria; Araújo,Ariane Gonçalves Silva de; Piazza,Thais; Ferreira,Vinicius Lins; Pontarolo,Roberto. |
| The aim of this study was to evaluate interruption of treatment with biological drugs and tofacitinib due to adverse events in patients with rheumatoid arthritis. A systematic review was performed in the electronic databases MEDLINE, Cochrane, Scopus, CRD, IPA, Lilacs and Scielo. Case reports addressing interruption of treatment due to any adverse event related to abatacept (ABA), adalimumab (ADA), anakinra (ANA), certolizumab pegol (CER), etanercept (ETA), golimumab (GOL), infliximab (IFX), rituximab (RTX), secukinumab (SEC), tocilizumab (TCZ), tofacitinib (TOF) or ustekinumab (UST) in rheumatoid arthritis patients were evaluated. Baseline data, patient profile, previous and current treatments, cause of discontinuation and information on reintroduction of... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Rheumatoid arthritis; Biological drugs/treatment interruption; Tofacitinib; Adverse events. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400617 |
| |
|
|
|
